Ikris Pharma Network Announces the Availability of Triokris™ (Trientine Dihydrochloride) to Support Patients Living With Wilson’s Disease
Noida, India — 15 January, 2026 – Ikris Pharma Network announced the availability of Triokris™ (Trientine Dihydrochloride 250 mg Capsules), a therapeutic option for patients diagnosed with Wilson’s Disease, a rare inherited disorder of copper metabolism. Triokris is designed to support clinicians in the management of patients requiring chelation therapy,